Introduction:
Resistant hypertension remains difficult to control and is associated with increased cardiovascular and renal risk. Baxdrostat, a selective aldosterone synthase inhibitor, has emerged as a potential therapeutic option for adults with uncontrolled or resistant hypertension. We evaluated the efficacy and...
A. Gadelmawla, A. Hageen, R. Rateb et al.· Circulation· 0 citations
This network meta‐analysis addresses the limited dose‐specific comparative evidence by evaluating different doses of tirzepatide (TZP) versus dulaglutide (DULA) for glycemic control, weight loss, and safety in type 2 diabetes mellitus (T2DM).
A. Hageen, A. Gadelmawla, A. O. Saleh et al.· Endocrinology, Diabetes & Me...· 0 citations
LAAC provides similar overall efficacy and safety compared with medical therapy for stroke prevention in AF but should currently remain reserved for selected patients rather than replacing oral anticoagulation broadly, indicating current evidence remains underpowered and additional randomized trials are needed.
A. AL-Janabi, A. Al-shammari, A. Hageen et al.· Cardiovascular Electrophysio...· 0 citations
Baxdrostat lowers blood pressure and aldosterone levels in uncontrolled and resistant hypertension but increases potassium and modestly reduces eGFR, supporting careful laboratory monitoring and longer trials to evaluate long-term clinical outcomes.
A. Gadelmawla, A. Hageen, R. Rateb et al.· Cardiology in Review· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.